Monosodium glutamate neonatal treatment induces cardiovascular autonomic function changes in rodents

Imagem de Miniatura
Arquivos
art_RODRIGUES_Monosodium_glutamate_neonatal_treatment_induces_cardiovascular_autonomic_function_2012.PDF (315.95 KB)
Citações na Scopus
17
Tipo de produção
article
Data de publicação
2012
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
HOSPITAL CLINICAS, UNIV SAO PAULO
Autores
KONRAD, Signora Peres
FARAH, Vera
MACHADO, Ubiratan Fabres
SCHAAN, Beatriz D'Agord
ANGELIS, Katia De
Citação
CLINICS, v.67, n.10, p.1209-1214, 2012
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
OBJECTIVES: The aim of this study was to evaluate cardiovascular autonomic function in a rodent obesity model induced by monosodium glutamate injections during the first seven days of life. METHOD: The animals were assigned to control (control, n = 10) and monosodium glutamate (monosodium glutamate, n = 13) groups. Thirty-three weeks after birth, arterial and venous catheters were implanted for arterial pressure measurements, drug administration, and blood sampling. Baroreflex sensitivity was evaluated according to the tachycardic and bradycardic responses induced by sodium nitroprusside and phenylephrine infusion, respectively. Sympathetic and vagal effects were determined by administering methylatropine and propranolol. RESULTS: Body weight, Lee index, and epididymal white adipose tissue values were higher in the monosodium glutamate group in comparison to the control group. The monosodium glutamate-treated rats displayed insulin resistance, as shown by a reduced glucose/insulin index (-62.5%), an increased area under the curve of total insulin secretion during glucose overload (39.3%), and basal hyperinsulinemia. The mean arterial pressure values were higher in the monosodium glutamate rats, whereas heart rate variability (>7 times), bradycardic responses (>4 times), and vagal (similar to 38%) and sympathetic effects (similar to 36%) were reduced as compared to the control group. CONCLUSION: Our results suggest that obesity induced by neonatal monosodium glutamate treatment impairs cardiac autonomic function and most likely contributes to increased arterial pressure and insulin resistance.
Palavras-chave
Monosodium Glutamate, Obesity, Arterial Pressure, Autonomic Function
URI
https://observatorio.fm.usp.br/handle/OPI/1537
Referências
  1. Borovikova LV, 2000, NATURE, V405, P458
  2. BRANDS MW, 1991, AM J PHYSIOL, V260, pR764
  3. Brito JO, 2008, BRAZ J MED BIOL RES, V41, P804, DOI 10.1590/S0100-879X2008005000030
  4. BUNYAN J, 1976, BRIT J NUTR, V35, P25, DOI 10.1079/BJN19760005
  5. CLOUGH RW, 1986, BRAIN RES BULL, V17, P51, DOI 10.1016/0361-9230(86)90160-7
  6. Cunha NV, 2010, LIFE SCI, V87, P375, DOI 10.1016/j.lfs.2010.07.014
  7. Davy KP, 2009, NEUROSCI BIOBEHAV R, V33, P116, DOI 10.1016/j.neubiorev.2008.05.024
  8. DEFRONZO RA, 1979, DIABETES, V28, P1095
  9. de Souza Claudio Teodoro, 2003, Physiological Chemistry and Physics and Medical NMR, V35, P43
  10. Farah V, 2006, AUTON NEUROSCI-BASIC, V130, P41, DOI 10.1016/j.autneu.2006.05.006
  11. Grassi G, 2004, J HYPERTENS, V22, P2363, DOI 10.1097/00004872-200412000-00019
  12. HALL JE, 1995, HYPERTENSION, V25, P994
  13. HALL JE, 1994, AM J HYPERTENS, V7, P772
  14. Haslam DW, 2005, LANCET, V366, P1197, DOI 10.1016/S0140-6736(05)67483-1
  15. Hellstrom HR, 2007, MED HYPOTHESES, V68, P415, DOI 10.1016/j.mehy.2006.031
  16. Krontoradova K, 2008, PHYSIOL RES, V57, P385
  17. La Rovere MT, LANCET, V14, P478
  18. LORDEN JF, 1986, NEUROTOXICOL TERATOL, V8, P509
  19. MARMO MR, 1994, BRAZ J MED BIOL RES, V27, P1249
  20. MARTINEZ FJ, 1994, HYPERTENSION, V23, P456
  21. Miller AW, 1999, J CARDIOVASC PHARM, V33, P698, DOI 10.1097/00005344-199905000-00004
  22. MOREAU P, 1995, J HYPERTENS, V13, P333
  23. Mozes S, 2004, PHYSIOL RES, V53, P415
  24. OIDA K, 1984, INT J OBESITY, V8, P385
  25. OLNEY JW, 1973, AM J CLIN NUTR, V26, P683
  26. OLNEY JW, 1969, SCIENCE, V164, P719, DOI 10.1126/science.164.3880.719
  27. Papa PD, 2002, LIFE SCI, V71, P1917
  28. Qadir E, 1996, AM J PHYSIOL-REG I, V270, pR450
  29. Quilliot D, 2001, CLIN AUTON RES, V11, P79, DOI 10.1007/BF02322050
  30. REHOREK A, 1987, BIOMED BIOCHIM ACTA, V46, P823
  31. Ribeiro BL, 2004, ARCH LATINOAM NUTR, V54, P58
  32. Richey JM, 1999, AM J HYPERTENS, V12, P405, DOI 10.1016/S0895-7061(98)00272-6
  33. Rodrigues B, 2011, CARDIOVASC DIABETOL, V10, DOI 10.1186/1475-2840-10-26
  34. Silva Renata Juliana da, 2011, Clinics (Sao Paulo), V66, P1793
  35. Su DF, 2002, ACTA PHARMACOL SIN, V23, P673
  36. Task Force of the European Society of Cardiology and the North American Society of Pacing Electrophysiology, 1996, CIRCULATION, V93, P1043, DOI [10.1161/01.CIR.93.5.1043, DOI 10.1161/01.CIR.93.5.1043]
  37. Thirone ACP, 2004, ENDOCRINOLOGY, V145, P281, DOI 10.1210/en.2003-0575
  38. Tokarev D, 1997, PHYSIOL RES, V46, P165
  39. TRIADOU N, 1982, DIABETES, V31, P75, DOI 10.2337/diabetes.31.1.75
  40. Valensi P, 2003, OBES RES, V11, P54, DOI 10.1038/oby.2003.10
  41. Van Gaal LF, 2006, NATURE, V444, P875, DOI 10.1038/nature05487
  42. Von Diemen Vinicius, 2006, Acta Cir Bras, V21, P425
  43. Zamo FS, 2010, CLINICS, V65, P85, DOI 10.1590/S1807-59322010000100013

Coleções
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/59